TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A review published in Science examines whether drugs used for obesity and type 2 diabetes could help preserve memory and other cognitive abilities. Animal findings and patient-record studies offer possible signals, but human evidence is mixed, and semaglutide did not slow early Alzheimer’s progression in two trials.
Researchers reviewing evidence on obesity drugs and brain health say medicines such as semaglutide and tirzepatide could affect memory and other cognitive abilities, but whether they preserve cognition in people remains unproven. The review, published in Science by researchers affiliated with the University of Gothenburg and the University of Copenhagen, calls for clinical trials that measure cognitive changes during treatment.
The researchers assessed evidence on drugs that act on glucagon-like peptide-1 (GLP-1) pathways, a group that includes semaglutide and tirzepatide. These medicines are used to treat obesity and type 2 diabetes. The review says they also influence biological processes relevant to brain function, though the available findings do not establish that the drugs protect memory in patients.
Animal studies indicate that GLP-1 drugs can affect learning and memory. Findings in people, however, are mixed. Analyses of patient records have linked GLP-1 treatment with a lower risk of dementia among people with type 2 diabetes, but those observational data cannot show that the drugs caused the difference or rule out other explanations.
Evidence from Alzheimer’s disease trials is also cautionary. In Novo Nordisk’s EVOKE and EVOKE+ clinical trials, semaglutide did not slow disease progression in patients with early Alzheimer’s disease, despite changes in several biological markers associated with the disease. The review authors say those results do not settle whether the drugs might affect cognition in other groups, including people with obesity or diabetes who do not have established Alzheimer’s disease.
The Patient Groups Still to Study
The question matters because some people with obesity or type 2 diabetes have difficulties with attention, planning and processing speed. The review links these problems in part to metabolic and vascular health, which may respond differently to treatment than the disease processes involved in Alzheimer’s. That possibility is a research rationale, not evidence that obesity medicines prevent cognitive decline.
Establishing whether cognition changes during treatment could help clarify who, if anyone, benefits and when treatment would need to begin. It could also distinguish a possible brain effect from improvements associated with changes in metabolism. For patients and clinicians, the review does not provide a new reason to use these medicines as memory treatments; it identifies questions that require testing.
Products Worth Considering
Blueair Blue Pure 511i Max Air Purifier
Levoit Core 600S-P Smart Air Purifier for Large Rooms
Bose Lifestyle Ultra Wireless Home Speaker, White Smoke
As an affiliate, we earn on qualifying purchases.
Evidence Beyond Alzheimer’s Trials
The review was commissioned by Science and authored by researchers from the University of Gothenburg and the University of Copenhagen. It considers evidence from animal research, patient-record studies and clinical trials rather than reporting a new trial of its own. Its central point is that effects on metabolism and biological processes related to the brain make the medicines relevant to investigate, but do not establish a cognitive benefit.
First author Stina Börchers, a researcher affiliated with both universities, said the team wants to determine whether treatment can help people with obesity or diabetes preserve cognitive abilities, particularly when started before problems become established. Senior author Christoffer Clemmensen, a research group leader at the University of Copenhagen, said separating direct brain effects from indirect effects through metabolic changes could inform future treatments aimed at cognitive function.
“By disentangling the direct and indirect effects of these drugs on the brain, we may ultimately be able to develop treatments specifically aimed at preserving cognitive function.”
— Christoffer Clemmensen, senior author of the review and a research group leader at the University of Copenhagen
Whether Cognition Improves in People
It remains unclear whether these medicines preserve memory or other cognitive abilities in people taking them for obesity or diabetes. The review does not report a new clinical trial demonstrating such a benefit. Patient-record associations cannot establish cause and effect, and animal findings do not by themselves predict human outcomes.
The researchers also say it is not yet clear whether any brain-related effects would arise from improved metabolism, direct action in the brain, or both, or which patients might benefit. The review flags a separate concern for older and frail patients: rapid weight loss and loss of muscle mass could impair physical function and reduce any potential overall benefit. The source material does not specify the size of that risk or identify which patients would be most affected.
Trials Must Track Cognitive Change
The researchers are calling for clinical trials that assess memory and other cognitive abilities from the start of treatment, rather than relying only on patient records or biological markers. Studies will need to clarify which patients are enrolled, how cognition changes over time and whether any differences can be attributed to the medicine.
They also call for monitoring older and frail participants for changes in physical function, including possible effects associated with rapid weight loss or muscle loss. Until such research provides clearer results, the review’s proposal remains a research direction; it does not change the established purpose of these drugs or show that they should be used to prevent cognitive decline.
Key Questions
Do obesity drugs protect memory?
That has not been established. The review describes relevant animal findings and mixed evidence in people, but it does not report proof that these drugs preserve memory.
What did the semaglutide Alzheimer’s trials find?
In Novo Nordisk’s EVOKE and EVOKE+ trials, semaglutide did not slow disease progression in people with early Alzheimer’s disease, although several biological markers changed.
Why do researchers think the drugs could affect cognition?
The medicines influence biological processes related to brain function, and metabolic and vascular health may be connected to cognitive difficulties such as problems with attention, planning and processing speed. These points support further study, not a confirmed treatment effect.
What research is needed next?
The review authors call for clinical trials that track cognition from treatment start and examine which patients might benefit. They also recommend monitoring older and frail patients for effects of rapid weight loss and muscle loss on physical function.
Source: news-medical.net
